T

Thor Medical ASA
OSE:TRMED

Watchlist Manager
Thor Medical ASA
OSE:TRMED
Watchlist
Price: 2.835 NOK 10.74% Market Closed
Market Cap: 665.8m NOK
Have any thoughts about
Thor Medical ASA?
Write Note

Net Margin
Thor Medical ASA

0%
Current
0%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-39.6m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
NO
Thor Medical ASA
OSE:TRMED
665.8m NOK N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
325.5B USD
9%
US
Amgen Inc
NASDAQ:AMGN
150.4B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.9B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
83.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.6B EUR
-14%
Country NO
Market Cap 665.8m NOK
Net Margin N/A
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 325.5B USD
Net Margin
9%
Country US
Market Cap 150.4B USD
Net Margin
13%
Country US
Market Cap 120.9B USD
Net Margin
-5%
Country US
Market Cap 115.7B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 83.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.6B EUR
Net Margin
-14%
No Stocks Found

Thor Medical ASA
Glance View

Market Cap
665.8m NOK
Industry
Biotechnology

Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 16 full-time employees. The company went IPO on 2014-07-07. The firm is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The firm is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

TRMED Intrinsic Value
0.124 NOK
Overvaluation 96%
Intrinsic Value
Price
T

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-39.6m
/
Revenue
0
What is the Net Margin of Thor Medical ASA?

Based on Thor Medical ASA's most recent financial statements, the company has Net Margin of 0%.